Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/3/11 → 02/22/17 |
Funding
- Merck and Company: $116,703.00
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
- Schuster, Michael (PI)
- Gabig, Theodore (CoPI)
- Lan, Fengshuo (CoPI)
- Richard, Shambavi (CoPI)
Project: Research